Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	25.91	26	110.78	85.08	16.6	6.68
Revenue Growth (YoY)	-68.68%	-76.53%	30.21%	412.60%	148.57%	639.42%
Gross Profit	25.91	26	110.78	85.08	16.6	6.68
Selling, General & Admin	44.34	40.58	23.86	20.94	18.91	16.39
Research & Development	62.95	71.84	72.38	68.74	54.51	42.74
Operating Expenses	107.29	112.42	96.24	89.67	73.42	59.13
Operating Income	-81.38	-86.42	14.54	-4.6	-56.82	-52.46
Interest Expense / Income	2.03	2.83	3.03	2.84	1.56	1.52
Other Expense / Income	190.46	149.46	-23.26	2.28	10.5	1.38
Pretax Income	-273.87	-238.71	34.77	-9.72	-68.88	-55.35
Income Tax	-19	-19	-0.61	15.97	0	0
Net Income	-254.87	-219.71	35.38	-25.69	-68.88	-55.35
Shares Outstanding (Basic)	5	5	5	4	3	2
Shares Outstanding (Diluted)	5	5	5	4	3	2
Shares Change	5.92%	6.33%	27.59%	12.97%	122.19%	103.44%
EPS (Basic)	-56.10	-49.80	7.20	-6.60	-20.40	-36.60
EPS (Diluted)	-56.10	-49.80	3.00	-6.60	-20.40	-36.60
Free Cash Flow	-58.99	-51.37	-32.83	-61.47	34.14	-51.36
Free Cash Flow Per Share	-10.90	-9.94	-6.80	-16.13	10.12	-33.83
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-314.15%	-332.32%	13.12%	-5.40%	-342.36%	-785.61%
Profit Margin	-983.83%	-844.91%	31.94%	-30.19%	-414.99%	-828.97%
Free Cash Flow Margin	-227.71%	-197.53%	-29.64%	-72.25%	205.70%	-769.21%
Effective Tax Rate	-	-	-1.75%	-	-	-
EBITDA	-269.18	-233.28	40.43	-4.51	-65.46	-51.8
EBITDA Margin	-1039.05%	-897.09%	36.49%	-5.30%	-394.40%	-775.86%
Depreciation & Amortization	2.67	2.6	2.62	2.37	1.86	2.03
EBIT	-271.85	-235.88	37.8	-6.88	-67.32	-53.83
EBIT Margin	-1049.36%	-907.08%	34.12%	-8.08%	-405.62%	-806.22%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).